精彩内容近日,东阳光药的HEC-301注射液获批临床,用于治疗超重或肥胖,该新药是公司第二款获批临床的生物药1类新药。近几年,东阳光药加速布局生物药市场,2020年至今已累计获批了5款胰岛素制剂,1类新药HEC88473注射液在今年2月已完成II期临床。图1:东阳光药最新获批临床的1类新药来源:CDE官网图2:生物药的销售情况(单位:万元)来源:米内网格局数据库在中国三大终端六大市场(统计范围见...
Source Link精彩内容近日,东阳光药的HEC-301注射液获批临床,用于治疗超重或肥胖,该新药是公司第二款获批临床的生物药1类新药。近几年,东阳光药加速布局生物药市场,2020年至今已累计获批了5款胰岛素制剂,1类新药HEC88473注射液在今年2月已完成II期临床。图1:东阳光药最新获批临床的1类新药来源:CDE官网图2:生物药的销售情况(单位:万元)来源:米内网格局数据库在中国三大终端六大市场(统计范围见...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.